Vanguard Group Inc Spruce Biosciences, Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

A detailed history of Vanguard Group Inc transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 843,844 shares of SPRB stock, worth $312,222. This represents 0.0% of its overall portfolio holdings.

Number of Shares
843,844
Previous 863,375 2.26%
Holding current value
$312,222
Previous $448,000 11.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$0.42 - $0.59 $8,203 - $11,523
-19,531 Reduced 2.26%
843,844 $396,000
Q1 2024

May 10, 2024
BUY
$0.7 - $5.49 $28,689 - $225,007
40,985 Added 4.98%
863,375 $682,000
Q4 2023

Feb 14, 2024
BUY
$1.04 - $2.93 $513,885 - $1.45 Million
494,121 Added 150.52%
822,390 $2.41 Million
Q3 2023

Nov 14, 2023
BUY
$2.04 - $2.54 $135,282 - $168,440
66,315 Added 25.32%
328,269 $741,000
Q2 2023

Aug 14, 2023
BUY
$1.92 - $2.6 $29,521 - $39,977
15,376 Added 6.24%
261,954 $563,000
Q1 2023

May 15, 2023
BUY
$1.15 - $3.17 $139,684 - $385,044
121,465 Added 97.08%
246,578 $544,000
Q4 2022

Feb 10, 2023
BUY
$0.99 - $1.43 $132 - $191
134 Added 0.11%
125,113 $137,000
Q3 2022

Nov 14, 2022
BUY
$1.18 - $2.19 $10,526 - $19,536
8,921 Added 7.69%
124,979 $171,000
Q2 2022

Aug 12, 2022
SELL
$1.28 - $2.23 $48,227 - $84,021
-37,678 Reduced 24.51%
116,058 $202,000
Q1 2022

May 13, 2022
SELL
$1.85 - $4.59 $404,023 - $1 Million
-218,391 Reduced 58.69%
153,736 $309,000
Q4 2021

Feb 14, 2022
BUY
$2.33 - $5.74 $2,975 - $7,329
1,277 Added 0.34%
372,127 $1.66 Million
Q3 2021

Nov 12, 2021
BUY
$6.01 - $11.26 $7,993 - $14,975
1,330 Added 0.36%
370,850 $2.23 Million
Q2 2021

Aug 13, 2021
BUY
$10.12 - $17.46 $3.74 Million - $6.45 Million
369,520 New
369,520 $4.14 Million

About SPRUCE BIOSCIENCES, INC.

SPRB Quotes by TradingView
  • Ticker SPRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,560,200
  • Market Cap $8.72M
  • Description
  • Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...
More about SPRB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email